Jazz Pharmaceuticals’ Zanidatamab Receives Positive CHMP Opinion for HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adop...

April 28, 2025 | Monday | News
Merck’s KEYTRUDA Significantly Improves Event-Free Survival in Resectable Head and Neck Cancer in Phase 3 KEYNOTE-689 Trial

Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizu...

April 28, 2025 | Monday | News
Pfizer’s Sasanlimab Plus BCG Significantly Extends Event-Free Survival in High-Risk NMIBC Patients in Phase 3 Trial

Pfizer Inc. announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination wi...

April 28, 2025 | Monday | News
Carnegie Mellon Researchers 3D Print Living Tissue Models Entirely from Collagen

Collagen is well-known as an important component of skin, but its impact is much greater, as it is the most abundant protein in the body, providing structu...

April 25, 2025 | Friday | News
Insmed Announces Landmark Phase 3 ASPEN Study Results Demonstrating Brensocatib’s Breakthrough Potential in Bronchiectasis

Insmed Incorporated, a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patie...

April 24, 2025 | Thursday | News
Adcentrx Therapeutics to Present First Clinical Data for ADC Candidate ADRX-0706 at 2025 ASCO Annual Meeting

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and...

April 24, 2025 | Thursday | News
Argent BioPharma Enters German Market with CannEpil® and CogniCann® Following Regulatory Approval

Argent BioPharma Ltd. , a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into th...

April 24, 2025 | Thursday | News
Antengene to Present Promising Clinical Data on ATG-037 and ATG-008 at 2025 ASCO Annual Meeting

Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commer...

April 24, 2025 | Thursday | News
Regeneron Expands U.S. Manufacturing with $3B+ Fujifilm Partnership to Boost Biologics Capacity

Regeneron Pharmaceuticals, Inc.  announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotec...

April 23, 2025 | Wednesday | News
Bristol Myers Squibb Reports Mixed Phase 3 ARISE Results for Cobenfy in Schizophrenia

 Bristol Myers Squibb  announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline...

April 23, 2025 | Wednesday | News
DESTINY-Breast09 Trial Shows Enhertu + Pertuzumab Significantly Improves PFS in 1st-Line HER2-Positive Metastatic Breast Cancer

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed Enhertu (trastuzumab deruxtecan) in co...

April 23, 2025 | Wednesday | News
Roche to Invest $50 Billion in U.S. Operations, Boosting Manufacturing, R&D, and Job Creation

Roche  announced  that it will invest USD 50 billion into the United States of America in the next five years. These investments further strength...

April 23, 2025 | Wednesday | News
HUTCHMED Completes Enrollment in Phase II Registration Trial of Savolitinib for MET-Amplified Gastric Cancer

HUTCHMED (China) Limited (“HUTCHMED”)  announces that it has completed enrollment of the registration phase of its Phase II trial of savol...

April 22, 2025 | Tuesday | News
Henlius Hosts World R&D Day 2025, Showcasing Innovation and Global Collaboration Under "Collaborate to Create" Theme

 Henlius  celebrated its World R&D Day 2025, under the theme "Collaborate to Create", bringing together senior executives, experts and indust...

April 21, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close